e-Therapeutics plc (AIM:ETX), the drug discovery and development
company, today announces its full year results for the 12 months ended
31 January 2014.
Positive interim results from lead cancer drug ETS2101
Progress and decisions on other programmes
Commenting on the results, Professor Malcolm Young, CEO of
"e-Therapeutics is making substantial progress in our clinical
programmes and in discovery, with four clinical trials ongoing in the UK
and US that are expected to generate further data in the next period.
Financially, the Company is well capitalised, with solid support from
its investors, and operationally, both locations in Oxford and Newcastle
are fully resourced and operating well. Consequently we have a clear,
unobstructed road forward on which to progress and the next few years
hold significant promise for the Company."
For the full release, please visit the company website at www.etherapeutics.co.uk.
[ Back To NFVZone's Homepage ]